Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.74 |
| ▸ | HTR1D | P28221 | 2/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144603 | 0.85 | HTR6 (1.00) | HTR6HTR1DMPOHTR1AHTR1B | |
| SCHEMBL3156829 | 0.83 | HTR6 (1.00) | HTR6HTR1DMPOHTR1AHTR1B | |
| SCHEMBL5655899 | 0.83 | HTR6 (0.73) | HTR6HTR1DMPOHTR1AHTR1B | |
| SCHEMBL3147480 | 0.82 | HTR6 (1.00) | HTR6HTR1DHTR1AHTR1B | |
| SCHEMBL1576005 | 0.77 | HTR6 (0.85) | HTR6HTR1A | |
| SCHEMBL3146752 | 0.77 | HTR6 (1.00) | HTR6MPO | |
| SCHEMBL4967323 | 0.77 | HTR6 (0.64) | HTR6HTR1DMPOHTR1AHTR1B | |
| SCHEMBL4004572 | 0.77 | HTR6 (0.54) | HTR6MPO | |
| SCHEMBL3139135 | 0.77 | HTR6 (0.66) | HTR6HTR1DMPOHTR1AHTR1B | |
| SCHEMBL3139127 | 0.77 | HTR6 (0.66) | HTR6HTR1DMPOHTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885HTR1D 27/4885MPO 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.